Program
becotatug
Also written as “JMT101”, “JMT101 Injection” and “JMT101 injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Nasopharyngeal Neoplasms, led by CSPC Pharmaceutical Group.
Furthest: phase 3, since Mar 13, 202411 company-led studies, 8 open or runningNext primary completion: Mar 26, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 118 open or running | phase 3since Mar 13, 2024 | Jun 16, 2020 | Mar 26, 2027phase 3 · NCT06380348 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
JMT101
, phase 3, as of Aug 20, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 16, 2020First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04448379 · 48 enrolled · China
- Dec 23, 2020Phase 1 study in Advanced Solid TumorNCT04689100 · 259 enrolled · China
- Nov 1, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05132777 · 155 enrolled
- Oct 13, 2023Phase 2 study in Colorectal NeoplasmsNCT06089330 · 102 planned
- Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerNCT06319313 · 534 planned
- Apr 9, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06380348 · 398 planned
- Apr 26, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06391944 · 161 enrolled · China
- Dec 7, 2024Phase 3 study in Locally Advanced or Metastatic Non-squamous NSCLCNCT06735391 · 516 planned · China
- Mar 21, 2025Phase 2 study in RecurrenceNCT06892431 · 150 planned
- Apr 25, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06989671 · 430 planned
- Aug 14, 2025Phase 3 study in Colorectal NeoplasmsNCT07134205 · 252 planned
Ahead
- Mar 26, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06380348
- Jun 1, 2027Primary completion: phase 3 study in Colorectal NeoplasmsNCT07134205
- Dec 30, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06989671
TargetBeta
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, becotatug targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferatio…”NCIt, read by Claude
“A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07134205Colorectal Neoplasms | 3 | Not yet recruiting | Jun 1, 2027 | 252 |
| NCT06989671Squamous Cell Carcinoma of Head and Neck | 2 | Not yet recruiting | Dec 30, 2027 | 430 |
| NCT06892431Recurrence | 2 | Not yet recruiting | Dec 31, 2025 | 150 |
| NCT06735391Locally Advanced or Metastatic Non-squamous NSCLC · China | 3 | Recruiting | Sep 30, 2026 | 516 |
| NCT06391944Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | May 17, 2023 | 161 |
| NCT06380348Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | Mar 26, 2027 | 398 |
| NCT06319313Squamous Cell Non-small Cell Lung Cancer | 3 | Not yet recruiting | Jul 1, 2026 | 534 |
| NCT06089330Colorectal Neoplasms | 2 | Not yet recruiting | Jul 2024 | 102 |
| NCT05132777Carcinoma, Non-Small-Cell Lung | 2 | UNKNOWN | Sep 30, 2023 | 155 |
| NCT04689100Advanced Solid Tumor · China | 1 | UNKNOWN | Dec 31, 2021 | 259 |
| NCT04448379Carcinoma, Non-Small-Cell Lung · China | 1 | UNKNOWN | Dec 31, 2021 | 48 |
How it is read
Names in the registry
- “JMT101”, 9 entries
- “JMT101 Injection”, 2 entries
- “JMT101 injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Colorectal Neoplasms, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Nasopharyngeal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.